Long-Acting HIV Injection Shows Promise for Patients Who Struggle with Daily Pills

The findings, published in the *New England Journal of Medicine*, come from the IMPALA trial — a study designed specifically for people living with HIV (human immunodeficiency virus) who have had trouble maintaining consistent daily medication routines. For many patients, missing doses of standard antiretroviral (anti-HIV) tablets can allow the virus to become detectable again, raising health risks and the chance of transmission.

The trial tested a long-acting injectable therapy, meaning patients receive an injection every one to two months rather than taking a pill every day. That shift in approach matters — adherence to daily medication is one of the most persistent challenges in HIV care globally, chiefly in sub-Saharan Africa where the trial was based.

For their part, the IMPALA study is classed as a phase 3b trial, which means it follows earlier large-scale testing and looks at how a treatment performs in specific real-world patient groups. The *New England Journal of Medicine* is one of the most widely read peer-reviewed medical journals in the world, and publication there carries considerable weight in clinical practice.

No detailed breakdown of the trial’s numerical results was included in the tweet posted by the journal’s account, @NEJM. The full data are available in the published paper.

—

If you are living with HIV and have concerns about your treatment or adherence, speak to your HIV specialist or GP in the first instance. NHS 111 can also advise on accessing the right service.

Key information

• NHS 111 — call 111 for non-emergency health advice, available 24 hours a day
• Terrence Higgins Trust helpline — 0808 802 1221, free and confidential support for people living with HIV
• Speak to your GP or HIV clinic before making any changes to your current medication